Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxaprozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.97 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.97 |
| ▸ | RXRA | P19793 | 19/20 | 0.97 |
| ▸ | RXRB | P28702 | 19/20 | 0.97 |
| ▸ | RXRG | P48443 | 15/20 | 0.97 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.97 |
| ▸ | C5 | P01031 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | DRD2 | P14416 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.97 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxaprozin SCHEMBL8190680 | 1.00 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL8191554 | 1.00 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL8191237 | 0.98 | RXRA (1.00) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL3286 | 0.98 | RXRA (1.00) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL3849972 | 0.98 | RXRA (1.00) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL5732754 | 0.97 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL6380181 | 0.97 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL28469762 | 0.97 | RXRA (0.97) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL10968776 | 0.95 | RXRA (0.94) | RXRARXRBRXRGNR4A2KDM4E | |
| Oxaprozin SCHEMBL8607424 | 0.94 | RXRA (0.91) | RXRARXRBRXRGNR4A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6030643-A | Potassium, sodium and tris oxaprozin salt pharmaceutical formulations | G.D. SEARLE & CO. (US) | 2000-02-29 | — | — | US | claimed |
| US-20240145031-A1 | Methods and devices for drug repositioning and drug repurposing as nuclear receptor modulators | Precision Medicine Lab (NL) | 2024-05-02 | — | — | US | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| US-11390868-B2 | Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity | CURNA, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20210290771-A1 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-09-23 | — | — | US | disclosed |
| US-11000597-B2 | Engineered receptor/ligand system for delivery of therapeutic agents | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-05-11 | — | — | US | disclosed |
| US-10722562-B2 | Combinatorial analysis and repair | IMMUDEX APS (DK) | 2020-07-28 | — | — | US | disclosed |
| WO-2020112814-A1 | DEVICES, SYSTEMS, AND METHODS TO MONITOR SUBJECT COMPLIANCE WITH A PHARMACEUTICAL TREATMENT REGIMEN | SAKAYA JAQUELINE MBWILLE (US) | 2020-06-04 | — | — | WO | disclosed |
| US-20200163616-A1 | DEVICES, SYSTEMS, AND METHODS TO MONITOR SUBJECT COMPLIANCE WITH A PHARMACEUTICAL TREATMENT REGIMEN | SAKAYA JACQUELINE MBWILLE (US) | 2020-05-28 | — | — | US | disclosed |
| US-10272241-B2 | Methods for modulating autophagy using remote ischemic conditioning | THE HOSPITAL FOR SICK CHILDREN (CA) | 2019-04-30 | — | — | US | disclosed |
| WO-2000058362-A1 | NEUTROKINE-ALPHA BINDING PROTEINS AND METHODS BASED THEREON | HUMAN GENOME SCIENCES, INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000056405-A2 | HUMAN TUMOR NECROSIS FACTOR RECEPTOR-LIKE 2 | HUMAN GENOME SCIENCES, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000056862-A1 | HUMAN TUMOR NECROSIS FACTOR RECEPTOR TR9 | HUMAN GENOME SCIENCES, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000053223-A1 | APOPTOSIS INDUCING MOLECULE II AND METHODS OF USE | HUMAN GENOME SCIENCES, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000050597-A2 | NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT | HUMAN GENOME SCIENCES, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000050459-A1 | HUMAN TUMOR NECROSIS FACTOR RECEPTOR-LIKE PROTEINS TR11, TR11SV1, AND TR11SV2 | HUMAN GENOME SCIENCES, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-2000050620-A2 | HUMAN ENDOKINE ALPHA AND METHODS OF USE | HUMAN GENOME SCIENCES, INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| US-6030643-A | Potassium, sodium and tris oxaprozin salt pharmaceutical formulations | G.D. SEARLE & CO. (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0901372-A1 | POTASSIUM, SODIUM AND TRIS OXAPROZIN SALT PHARMACEUTICAL FORMULATIONS | G.D. SEARLE & CO. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997044022-A1 | POTASSIUM, SODIUM AND TRIS OXAPROZIN SALT PHARMACEUTICAL FORMULATIONS | G.D. SEARLE & CO. (US) | 1997-11-27 | — | — | WO | disclosed |